| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
|
Lancet
|
2008
|
19.58
|
|
2
|
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
|
N Engl J Med
|
2011
|
13.74
|
|
3
|
Everolimus for advanced pancreatic neuroendocrine tumors.
|
N Engl J Med
|
2011
|
11.55
|
|
4
|
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
|
Lancet
|
2013
|
5.82
|
|
5
|
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
|
Lancet
|
2012
|
5.67
|
|
6
|
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
|
J Clin Oncol
|
2008
|
5.28
|
|
7
|
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
|
Lancet
|
2011
|
4.79
|
|
8
|
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
|
Blood
|
2004
|
3.84
|
|
9
|
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
|
J Clin Oncol
|
2009
|
3.18
|
|
10
|
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
|
J Clin Oncol
|
2013
|
2.14
|
|
11
|
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
|
J Clin Oncol
|
2011
|
2.08
|
|
12
|
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
|
J Clin Oncol
|
2011
|
2.05
|
|
13
|
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
|
J Clin Oncol
|
2007
|
1.93
|
|
14
|
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
|
Adv Ther
|
2013
|
1.90
|
|
15
|
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.
|
J Hematol Oncol
|
2009
|
1.70
|
|
16
|
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
|
J Clin Oncol
|
2007
|
1.60
|
|
17
|
Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.
|
Clin Cancer Res
|
2011
|
1.46
|
|
18
|
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
|
Eur J Cancer
|
2005
|
1.42
|
|
19
|
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
|
J Clin Oncol
|
2007
|
1.32
|
|
20
|
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.
|
J Clin Oncol
|
2003
|
1.27
|
|
21
|
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
|
Cancer Chemother Pharmacol
|
2005
|
1.13
|
|
22
|
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
|
J Natl Cancer Inst
|
2013
|
1.10
|
|
23
|
Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
|
Cancer Chemother Pharmacol
|
2008
|
1.04
|
|
24
|
Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).
|
Invest New Drugs
|
2005
|
0.98
|
|
25
|
Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat).
|
J Clin Oncol
|
2008
|
0.85
|
|
26
|
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.
|
J Clin Oncol
|
2004
|
0.84
|
|
27
|
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
|
Semin Oncol
|
2006
|
0.84
|
|
28
|
A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
|
Anticancer Res
|
2010
|
0.83
|
|
29
|
A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.
|
Gynecol Oncol
|
2002
|
0.80
|
|
30
|
Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies.
|
Invest New Drugs
|
2002
|
0.78
|